Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
KC-WISE
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
- NCT05427383 ↗
- Recruiting
- Shanghai JMT-Bio Inc.
- Standard
We haven't built an HCP commentary report on KC-WISE (KN026/Placbo, paclitaxel and 2 more in Stomach Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KC-WISE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 16 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Stomach Cancer
- Interventions
- KN026/Placbo Injection; Paclitaxel Injection; Docetaxel Injection; Irinotecan Injection
- Arms
- KN026 + Paclitaxel/ Docetaxel/ Irinotecan · Experimental
- Placebo + Paclitaxel/ Docetaxel/ Irinotecan · Experimental
- Enrollment
- 286 (estimated)
- Primary outcomes
- Progression Free Survival (PFS) according to RECIST 1.1 by IRC
- Overall Survival (OS) according to RECIST 1.1 by IRC
- Sponsor
- Shanghai JMT-Bio Inc.
- Start
- Apr 7, 2022
- Primary completion
- Nov 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05427383 · updated Dec 19, 2023